U.S. Markets

UK's MHRA authorises orforglipron (LLY), making the UK the first Country in Europe to approve this glp-1 tablet for weight management and type 2 Diabetes

StockNow breaking-news AI analysis

UK MHRA authorized Eli Lilly's orforglipron as Europe's first GLP-1 tablet for weight and diabetes, following clinical data showing superior efficacy over oral semaglutide and enhanced patient convenience.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more